- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04747041
Evaluation of a Phyto Aromatherapy Treatment in the Management of Recurrent Cystitis (CYSTALTERNA)
Evaluation of a Phyto Aromatherapy Treatment in the Management of Recurrent Cystitis Preliminary Study
Half of the women have a once-in-a-lifetime episode of cystitis. Recurrence occurs in about 20% to 30% of patients, and half of these patients will have more than 4 episodes per year, defining recurrent cystitis.
The clinical assessment sometimes brings to light favourable factors; variables in pre- or post-menopause; but in the majority of cases, no explanatory cause can solve the problem and some authors refer to resignation as a classic reaction to this problem.
several countries have already opted for alternative treatments (Nonsteroidal anti-inflammatory drugs, phytotherapy, diuresis treatment), especially since the pressure of antibiotic selection is at the root of the dramatic spread of bacterial resistances.
There is a growing interest in the potential of complementary medicine to assist in this care. Products based on cranberries, for example, have been particularly studied and a 2012 Cochrane review concluded that there is a benefit with an estimated risk reduction of between 10 and 20%. Another "alternative" approach is the use of Chinese medicinal herbs. These herbs have been used for more than 2000 years.
The implementation of phyto-aromatherapy treatment implies a global management of patients with recurrent cystitis. Initially, it involves a curative phase as soon as the first symptoms of the attack appear, thanks to a mixture of antibacterial essential oils. In a second phase, it integrates a preventive phase over several months thanks to an association of medicinal plants whose effects in this field have been proven in vitro and in vivo, allowing to rebalance a "terrain" associating anxiety, hypersensitivity to pain, a terrain willingly associated with the irritable bowel syndrome in these patients. While having few side effects, the plants will act, in the long term, at different levels: directly on the cause of the disease thanks to their antiseptic, antiadhesive and diuretic activities, but also by reducing the symptoms thanks to their anti-inflammatory, analgesic, antispasmodic and anxiolytic activities.
Investigators hypothesize that patients with recurrent cystitis can be improved by a two-phase, multi-plant, phyto-aromatherapy treatment combining several plants: the treatment of attacks, by aromatherapy, and a prophylactic treatment, by phytotherapy. In the absence of any such studies published in the literature, investigators propose a non-randomised prospective monocentric interventional pilot study on 15 patients with proof of concept and feasibility.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Véronique MONDAIN
- Phone Number: +33 0492035466
- Email: mondain.v@chu-nice.fr
Study Contact Backup
- Name: Pascale GELIS-IMBERT
- Phone Number: +33 0664231660
- Email: 3.14phyt@gmail.com
Study Locations
-
-
-
Nice, France, 06202
- Hôpital Archet
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Women aged 18 or older.
- Affiliated to social security.
- Presenting recurrent cystitis defined by a frequency of at least 4 episodes per year.
- For women of childbearing age: effective contraception followed for at least 3 months prior to the start of the study and agreeing to keep it throughout the study period
- Available to consult a phyto-aromatherapy pharmacist for an initial consultation and then every 3 months (M3, 6,9, 12) and then at 18 months.
- Having been previously explored according to good practice and informed
- Having signed the informed consent
Exclusion Criteria:
- Pregnant or breastfeeding women
- Severe visceral deficiencies in the previous year.
- Individualised psychiatric pathology.
- Other progressive infectious pathologies requiring antibiotic treatment.
- Taking anticoagulants.
- Concomitant intake of non-drug treatments.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Alternating each month for 1 year between Phytocyst herbal tea and Cyscontrol
Alternating each month (From Day1 to DAY15) for 1 year between Phytocyst herbal tea and Cyscontrol = Preventive Treatment In case of episode of cystitis : AROMAFEMINA, Capsules for the comfort of the urinary tract Oleocaps 2 : 2 capsules before meals, 3 times a day for 5 consecutive days.
|
Alternating every month from Day1 to Day15 cyscontrol and phytocyst herbal tea to prevent episode of cystitis
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
adherence to phyto-aromatherapy treatment
Time Frame: 12th month
|
The scale called "treatment compliance" ranges from 1 to 10.
A score of 1 means not at all observant and 10 means very observant.
|
12th month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Antibiotic treatments
Time Frame: 12 months
|
The number of antibiotic treatments over 12 months
|
12 months
|
Number of cystitis
Time Frame: 12 months
|
The number of cystitis over the 12 months of the protocol
|
12 months
|
Patients' overall satisfaction
Time Frame: 12 months
|
Patients' overall satisfaction will be assessed on a simple numerical scale from 1 to 10.
The scale is called the "General Satisfaction Scale" and ranges from 1 to 10.
A score of 1 means not at all satisfied and 10 means very satisfied.
As well as their ability to manage their symptoms.
Three analogue scales will also be used to assess the impact of the protocol on patients' sexuality (including anxiety and comfort in relation to intercourse, when appropriate)
|
12 months
|
Recording adverse events
Time Frame: 18 months
|
The nature of the side effects, sought and at each phyto-aromatherapy consultation
|
18 months
|
The benefit persisting at 6 months after stopping treatment with phyto-aromatherapy
Time Frame: During 6 months after stopping treatment (patient stop treatment at Month12 so between the 12th and 18th month)
|
The benefit persisting at 6 months after stopping treatment with phyto-aromatherapy will be evaluated on the number of times antibiotic therapy is used over a period of 6 months after stopping the treatment
|
During 6 months after stopping treatment (patient stop treatment at Month12 so between the 12th and 18th month)
|
Evaluation of the evolution of bacterial resistance on phenotypes isolated from the cytobacteriological examination of urine
Time Frame: From date of inclusion until the date of documented episode of cystitis, assessed up to 18 months
|
Evaluation of the evolution of bacterial resistance on phenotypes isolated from the cytobacteriological examination of urine if inclusion resistance markers are present, in comparison with the last cytobacteriological examination of urine carried out during the protocol period, requested in the event of a clinical episode.
A cytobacteriological examination of the urine carried out on a systematic basis that can detect asymptomatic colonisation or bacteriuria is not appropriate.
|
From date of inclusion until the date of documented episode of cystitis, assessed up to 18 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Veronique MONDAIN, Centre Hospitalier Universitaire de Nice
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 17-AOIP-02
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cystitis Recurrent
-
CEN BiotechNexira; CEN NutrimentCompletedRecurrent CystitisFrance
-
University of California, San DiegoTerminatedPainful Bladder Syndrome | Recurrent Urinary Tract Infection | Chronic Interstitial CystitisUnited States
-
Johns Hopkins UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University...Enrolling by invitationUrinary Tract Infections | Recurrent Urinary Tract Infection | Cystitis RecurrentUnited States
-
Aalborg University HospitalAalborg UniversityRecruitingLactobacillus Infection | Cystitis RecurrentDenmark
-
Samsung Medical CenterCompletedRecurrent CystitisKorea, Republic of
-
Asan Medical CenterCompletedChronic Interstitial CystitisKorea, Republic of
-
St. Louis UniversityTerminated
-
St. Louis UniversityCompletedInterstitial Cystitis
-
Northwell HealthWithdrawnInterstitial CystitisUnited States
Clinical Trials on CYSCONTROL/PHYTOCYST Herbal tea
-
Aberystwyth UniversityTeTrimTeas CyfActive, not recruitingObesity | Well-beingUnited Kingdom
-
Medical University of South CarolinaTraditional Medicinals CorporationCompletedLactationUnited States
-
Composite Interceptive Med ScienceComposite Interceptive Med-Science Laboratories Pvt LtdUnknown
-
Taichung Tzu Chi HospitalRecruitingNon-alcoholic Fatty Liver DiseaseTaiwan
-
University of ArizonaUnited States Department of DefenseCompletedLung Cancer Prevention
-
National Cheng Kung UniversityBuddhist Tzu Chi General Hospital; E-DA Hospital; Tzu Chi UniversityNot yet recruitingQuality of Life | Dementia | Caregiver Burden
-
Transtimulation Research, IncNational Center for Complementary and Integrative Health (NCCIH); Texas Tech... and other collaboratorsCompleted
-
Dr.Ruba MusharbashUnknown
-
Instituto Politécnico de BragançaRecruiting
-
Buddhist Tzu Chi General HospitalCompletedFunctional Gastrointestinal Disorders | Healthy SubjectsTaiwan